Tocilizumab

Tocilizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IL-6 receptor
Clinical data
Trade names	Actemra, Roactemra
Biosimilars	tocilizumab-aazg, tocilizumab-bavi, Tofidence, Tyenne
AHFS/Drugs.com	Monograph
MedlinePlus	a611004
License data	US DailyMed: Tocilizumab;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous, subcutaneous
ATC code	L04AC07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only and Emergency Use Authorization; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	8–14 days during steady state (dependent on concentration)
Identifiers
CAS Number	375823-41-9 ;
DrugBank	DB06273 ;
ChemSpider	none;
UNII	I031V2H011;
KEGG	D02596 ;
ChEMBL	ChEMBL1237022 ;
Chemical and physical data
Formula	C6428H9976N1720O2018S42
Molar mass	144987.06 g·mol−1
	(what is this?) (verify)

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Tocilizumab was approved for medical use in the European Union in January 2009, and in the United States in January 2010.